National Center for Advancing Translational Sciences; Notice of Meetings, 18040-18041 [2014-07016]
Download as PDF
<![CDATA[
18040
Federal Register / Vol. 79, No. 61 / Monday, March 31, 2014 / Notices
on February 3, 2011, PCT Application
Number PCT/US2012/23575, filed on
February 2, 2012, U.S. Patent
Application Number 13/983,545, filed
on August 2, 2013, European Patent
Application Number 12702953.6, filed
on February 2, 2012, and Canadian
Patent Application Number 2826594,
filed on February 2, 2012, to Exxell BIO,
Inc., having a place of business in
Shoreview, Minnesota, United States of
America. The patent rights in these
inventions have been assigned to the
United States of America and Thomas
Jefferson University.
Only written comments and/or
application for a license which are
received by the NIH Office of
Technology Transfer on or before April
30, 2014 will be considered.
DATES:
Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Peter Soukas, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Email:
ps193c@nih.gov; Telephone: (301) 435–
4646; Facsimile: (301) 402–0220.
ADDRESSES:
No
vaccine candidates against Ebola virus
(EBOV) or Marburg virus (MARV) are
nearing licensure, and the need to
develop a safe and efficacious vaccine
against filoviruses continues. Whereas
several preclinical and clinical vaccine
candidates against EBOV or MARV exist
(please see below for further
elaboration), their further development
is a major challenge based on safety
concerns, pre-existing vector immunity,
issues such as manufacturing, dosage,
and marketability, and funding for
development. The inventors have
developed a new platform based on live
or chemically inactivated (killed) rabies
virus (RABV) virions containing EBOV
glycoprotein (GP) in their envelope. In
preclinical trials, immunization with
such recombinant RABV virions
provided excellent protection in mice
against lethal challenge with the mouse
adapted EBOV and RABV. More
specifically, the inventors have
developed a trivalent filovirus vaccine
based on killed rabies virus virions for
use in humans to confer protection from
all medically relevant filoviruses and
RABV. Two additional vectors
containing EBOV Sudan GP or MARV
GP are planned to be constructed in
addition to the previously developed
EBOV Zaire GP containing vaccine. Live
attenuated vaccines have been
developed for use in at risk nonhuman
primate populations in Africa and
tkelley on DSK3SPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
18:10 Mar 28, 2014
Jkt 232001
inactivated vaccines have been
developed for use in humans.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published Notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.
The fields of use may be limited to (1)
inactivated vaccines against rabies virus
and filoviruses for use in humans and
(2) live attenuated vaccines against
rabies virus and filoviruses for use in
non-human animals.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: March 26, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–07023 Filed 3–28–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
contract proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications
and contract proposals, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Emphasis Panel; NIH Loan Repayment
Program (Clinical and Pediatric Researchers).
Date: April 24, 2014.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Room 3094, Morrisville, NC
27560; (Virtual Meeting).
Contact Person: RoseAnne M. McGee,
Associate Scientific Review Administrator,
Scientific Review Branch, Division of
Extramural Research and Training, Nat.
Institute of Environmental Health Sciences,
P.O. Box 12233, MD EC–30, Research
Triangle Park, NC 27709, (919) 541–0752,
mcgee1@niehs.nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Career Grant Applications
Review in Environmental Health Sciences.
Date: April 24, 2014.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Room 3118, Morrisville, NC
27560, (Telephone Conference Call).
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research and Training, Nat. Institute of
Environmental Health Sciences, P.O. Box
12233, MD EC–30/Room 3171, Research
Triangle Park, NC 27709, (919) 541–0670,
worth@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: March 25, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–07021 Filed 3–28–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the National
Center for Advancing Translational
Sciences.
E:\FR\FM\31MRN1.SGM
31MRN1
Federal Register / Vol. 79, No. 61 / Monday, March 31, 2014 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cures Acceleration
Network Review Board.
Date: May 16, 2014.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Danilo A Tagle, Ph.D.,
Executive Secretary, National Center for
Advancing Translational Sciences, 1
Democracy Plaza, Room 992, Bethesda, MD
20892, 301–594–8064, Danilo.Tagle@nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Advisory
Council.
Date: May 16, 2014.
Open: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director
and other staff.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Closed: 3:15 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Danilo A Tagle, Ph.D.,
Executive Secretary, National Center for
Advancing Translational Sciences, 1
Democracy Plaza, Room 992, Bethesda, MD
20892, 301–594–8064, Danilo.Tagle@nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Dated: March 25, 2014.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–07016 Filed 3–28–14; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
18:10 Mar 28, 2014
Jkt 232001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
18041
additional information for the meeting will
be posted when available.
Dated: March 25, 2014.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–07019 Filed 3–28–14; 8:45 am]
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council for
Biomedical Imaging and Bioengineering.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering; NACBIB May, 2014.
Date: May 20, 2014.
Open: 9:15 a.m. to 12:00 p.m.
Agenda: Report from the Institute Director,
other Institute Staff, scientific presentations,
and presentation of workgroup report.
Place: The William F. Bolger Center,
Franklin Building, Conference Room 1, 9600
Newbridge Drive, Potomac, MD 20854.
Closed: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: The William F. Bolger Center,
Franklin Building, Conference Room 1, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Anthony Demsey, Ph.D.,
Director, National Institute of Biomedical
Imaging and Bioengineering, 6707
Democracy Boulevard, Room 241, Bethesda,
MD 20892.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib1.nih.gov/about/NACBIB/
NACBIB.htm, where an agenda and any
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Nephrolithiasis
Outcomes Studies.
Date: April 16, 2014.
Time: 7:30 p.m. to 10:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Carol J. Goter-Robinson,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 748, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7791, goterrobinsonc@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; 2014 LRP
Applications.
Date: April 25, 2014.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: John F. Connaughton,
Ph.D., Chief, Training and Mentored
Research Section, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
753, 6707 Democracy Boulevard, Bethesda,
E:\FR\FM\31MRN1.SGM
31MRN1
]]>Agencies
[Federal Register Volume 79, Number 61 (Monday, March 31, 2014)]
[Notices]
[Pages 18040-18041]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07016]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of meetings of the
National Center for Advancing Translational Sciences.
[[Page 18041]]
The meetings will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Cures Acceleration Network Review Board.
Date: May 16, 2014.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director.
Place: National Institutes of Health, Building 31, Conference
Room 10, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Danilo A Tagle, Ph.D., Executive Secretary,
National Center for Advancing Translational Sciences, 1 Democracy
Plaza, Room 992, Bethesda, MD 20892, 301-594-8064,
Danilo.Tagle@nih.gov.
Name of Committee: National Center for Advancing Translational
Sciences Advisory Council.
Date: May 16, 2014.
Open: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director and other staff.
Place: National Institutes of Health, Building 31, Conference
Room 10, 31 Center Drive, Bethesda, MD 20892.
Closed: 3:15 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, Conference
Room 10, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Danilo A Tagle, Ph.D., Executive Secretary,
National Center for Advancing Translational Sciences, 1 Democracy
Plaza, Room 992, Bethesda, MD 20892, 301-594-8064,
Danilo.Tagle@nih.gov.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Dated: March 25, 2014.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-07016 Filed 3-28-14; 8:45 am]
BILLING CODE 4140-01-P
